Sorrento Therapeutics has acquired a majority stake in Zhengzhou Fortune Bioscience (Zhengzhou FortuneBio), a Chinese diagnostic manufacturer, for an undisclosed price. According to Sorrento Therapeutics, the acquisition is in response to drastic increasing demands around the world and planned product build-up expecting possible additional approvals for its COVISTIX Covid-19 virus rapid antigen detection test. Zhengzhou […]
Sorrento Therapeutics said that STI-1499, its anti-SARS-CoV-2 antibody, showed 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration. The US biotech company will look to create an antibody cocktail product that will work as a protective shield against SARS-CoV-2 coronavirus infection and stay effective even […]
Sorrento Therapeutics, a California-based biopharma company, has turned down a takeover bid worth about $993 million from an undisclosed private equity fund, as per the latest pharma acquisition news. Earlier this month, the US biopharma company was offered $7.00 per share for the acquisition of a majority stake or 100% in the former. Sorrento Therapeutics […]